4/A: KALA BIO Director Amends SEC Filing to Correct Insider Stock Sale Details

KALA BIO, Inc. Director Mark T. Iwicki filed an amended Form 4 to clarify a previously reported acquisition of common stock was, in fact, a disposition of 10,866 shares at a weighted average price of $3.74 to cover tax obligations.

Summary

• Mark T. Iwicki, a Director of KALA BIO, Inc., filed an amended Form 4 (Form 4/A) to correct a previously reported transaction.
• The original filing on June 4, 2025, incorrectly stated an acquisition of common stock.
• The amendment clarifies that the transaction on June 3, 2025, was a disposition (sale) of 10,866 shares of KALA BIO common stock.
• The shares were sold at a weighted average price of $3.74, with individual sales ranging from $3.52 to $4.05.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Iwicki on November 9, 2020.
• The purpose of the sale was to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs) granted on May 31, 2023.
• Following this transaction, Mark T. Iwicki beneficially owns 269,210 shares of KALA BIO common stock, which includes 154,042 unvested RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine, pre-planned insider sale for tax purposes, which is a common occurrence and not indicative of management's view on the company's prospects. The amendment corrects an administrative error in reporting.

Negatives

• The need for an amendment indicates an initial error in reporting, which could suggest minor administrative oversight in the original filing process.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020, to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ('RSUs') granted on May 31, 2023.
• This amendment is being filed solely to correct the nature of the transaction reported in Column 4 of Table I of the Form 4 filed by the Reporting Person on June 4, 2025. As reported in this amendment, such transaction resulted in a 'disposition' of common stock by the Reporting Person and not an 'acquisition' as previously reported.

Industry Context

This filing is a routine regulatory disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the director's direct holdings, but it was pre-planned and for tax purposes, which typically has minimal impact on investor sentiment. The correction ensures accurate public record of insider activity.

Key Dates

Keywords

KALA BIO, KALA, SEC Form 4/A, Insider Trading, Stock Sale, Beneficial Ownership, Mark T. Iwicki, Restricted Stock Units, RSU, 10b5-1 Plan, Tax Withholding